Thailand's Regulatory Framework for Psilocybin Manufacturing and Export

Thailand occupies a unique position in the global psychedelic pharmaceutical landscape. As of 2024, it is one of only a handful of countries worldwide — alongside Canada and South Africa — where a clear, legal pathway exists for the licensed manufacture of psilocybin for medical and research purposes. For pharmaceutical companies, clinical trial sponsors, and research institutions seeking reliable psilocybin API supply, understanding Thailand's regulatory architecture is essential.

This article provides a detailed overview of the current legal framework, licensing pathway, and export requirements for psilocybin manufacturing in Thailand, based on the statutory instruments and regulatory guidance in effect as of early 2026.

The Dual Classification System

Thailand's approach to psilocybin regulation involves a dual classification that creates important distinctions between the raw material and the purified compound.

Psilocybin-containing mushrooms — specifically Psilocybe cubensis — are classified as Category 5 narcotics under the Narcotics Act B.E. 2522 (1979), as amended. Category 5 is the least restrictive narcotics classification under Thai law. Cannabis was formerly in this same category before its partial decriminalization, establishing a regulatory precedent for progressive reform of Category 5 substances.

The purified compound psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is separately classified as a Category 1 Controlled Psychotropic Substance under the Psychotropic Substances Act B.E. 2559 (2016). This dual classification creates regulatory complexity but also provides a workable pathway: cultivation of the mushroom material falls under the more permissive Category 5 framework, while handling of the purified API requires the additional psychotropic substance controls.

The April 2024 Ministerial Notification

The pivotal regulatory development was a Ministerial Notification issued under the Narcotics Code, effective April 23, 2024. This notification explicitly permits the cultivation and use of psilocybin mushrooms for medical treatment and research purposes, subject to licensing from the Minister of Public Health.

This notification was significant for several reasons. It established an affirmative legal basis for psilocybin mushroom cultivation — not merely a tolerance or enforcement discretion, but a positive grant of permission under the statutory framework. It aligned Thailand with its broader national strategy of positioning itself as a regional hub for pharmaceutical manufacturing and biotech innovation. And it created the necessary legal foundation for the downstream activities of extraction, purification, and manufacturing of psilocybin API.

The Manufacturing License Pathway

Obtaining authorization to manufacture psilocybin API in Thailand requires navigating several regulatory bodies and obtaining multiple approvals. The primary instrument is the narcotics manufacturing license, applied for through the Thai Food and Drug Administration (Thai FDA) using Form YS-5.

Thai FDA — Narcotics Manufacturing License

The Form YS-5 application covers the authorization to manufacture narcotics (in this case, the cultivation of psilocybin mushrooms and their processing into API). The Thai FDA has established a fast-track pathway targeting 90-day approval for compliant applications, although in practice timelines can vary depending on the completeness of the application and the specific facility requirements.

Key requirements for the manufacturing license include demonstration of appropriate facility standards, qualified personnel (including a Thai-licensed pharmacist serving as the Qualified Person), documented standard operating procedures, and security measures meeting ONCB specifications.

ONCB — Security and Operational Compliance

The Office of the Narcotics Control Board (ONCB) oversees security requirements for any facility handling narcotics or psychotropic substances. ONCB compliance covers physical security measures (access controls, surveillance, secure storage), inventory management and chain-of-custody documentation, personnel background verification, and waste handling and destruction protocols for controlled substance waste.

GMP Certification

For pharmaceutical-grade API production intended for clinical use or export to regulated markets, GMP (Good Manufacturing Practice) certification from the Thai FDA is essential. The GMP certification process typically requires 6–9 months and covers facility design, equipment qualification, process validation, quality control systems, and documentation practices.

GMP certification is particularly critical for export-oriented manufacturers, as destination country regulators (such as Australia's TGA, Health Canada, or the European EMA) require evidence that the API was manufactured under GMP conditions as a prerequisite for import authorization.

Export Licensing and International Trade

Exporting psilocybin from Thailand is a multi-jurisdictional process that requires authorizations from both the exporting and importing countries.

Thai Export Requirements

Each shipment of psilocybin requires an individual export permit from the ONCB. The export permit application must include the identity and licensing status of the receiving party, the quantity and specification of the material being shipped, evidence that the destination country has authorized the import, and documentation including Certificate of Analysis and batch records.

Destination Country Import Requirements

The importing entity must obtain valid import authorization from their national regulatory authority. For the key current markets, the requirements include authorisation from Australia's Office of Drug Control (ODC) for import of scheduled substances, Health Canada authorization under the Controlled Drugs and Substances Act (CDSA) via the Special Access Programme or research exemption pathways, and for academic research institutions in other jurisdictions, authorization from the relevant national narcotics control authority.

The bilateral nature of this process means that manufacturers must maintain active relationships with regulatory authorities in both Thailand and their target export markets, and must have the documentation and compliance infrastructure to satisfy both sets of requirements simultaneously.

BOI Investment Incentives

Thailand's Board of Investment (BOI) offers significant incentive packages for export-oriented biotech and pharmaceutical manufacturing operations. If approved, BOI incentives can include up to 8 years of corporate income tax exemption, 5 years of machinery import duty exemption, and permission for foreign majority ownership — a significant consideration for international investors in a jurisdiction that otherwise restricts foreign business ownership in certain sectors.

BOI applications framed as export-oriented biotech manufacturing have historically achieved high approval rates, particularly when the proposed facility aligns with Thailand's national economic development priorities in the pharmaceutical sector.

Regulatory Outlook

Thailand's regulatory framework for psilocybin manufacturing is still maturing. Several developments are worth monitoring. The Thai FDA is building institutional expertise in psychedelic pharmaceutical regulation, which should streamline future licensing processes. International regulatory harmonization — particularly between Thailand and key destination markets — continues to evolve. And the global clinical trial landscape, especially the progress of psilocybin toward FDA approval in the United States, will influence the scale and urgency of demand for Thai-manufactured API.

For manufacturers and their international partners, the current period represents a window of opportunity to establish regulatory approvals and operational capabilities in advance of the anticipated growth in global demand.

The regulatory infrastructure exists. The legal pathway is clear. The strategic question for the industry is not whether psilocybin API can be manufactured in Thailand, but who will be best positioned when global demand scales.